11 completed, 2 recruiting, 2 unknown, 1 terminated. 17 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 11, Recruiting 2, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 1, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Malignancy: new trials by email Literature Review of Malignancy trials Research Report on Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository Informatics system for eligibility monitoring, Standard eligibility monitoring - Malignancy, Immune Related Adverse Events | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 100 | 2025-06-17 | 2025-06-19 |
| Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells Commercial CAR-T, Investigational CAR-T - Malignancy, Cancer | Phase 1 / Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2025-01-20 | 2026-01-06 | |
| Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) - Cancer, Malignancy | Phase 1 | Recruiting | CytoMed Therapeutics Pte Ltd | 12 | 2024-11-19 | 2024-11-22 |
| Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal Tumors Lipopolysaccharide - Abdominal Cancer, Malignancy | Phase 1 | Completed | Patrick Wagner, MD, FACS | 12 | 2023-03-16 | 2026-06-15 |
| A Clinical Study of 68Ga-HX01 Injection for PET Imaging 68Ga-HX01 Injection(0.05mCi/kg), 68Ga-HX01 Injection(0.1mCi/kg), 68Ga-HX01 Injection(0.07mCi/kg) - Healthy, Malignancy | Phase 1 | Completed | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | 22 | 2022-12-29 | 2024-05-16 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 AK114 - Advanced or Metastatic Solid Tumors, Malignancy | Phase 1 | Unknown | Akeso | 30 | 2022-03-15 | 2022-01-20 |
| Treatment of Malignant Tumors With NK Cell Decitabine combined with NK cell infusion - Malignancy | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 60 | 2021-02-05 | 2021-12-03 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| A Study of ASN007 in Patients With Advanced Solid Tumors ASN007: ascending doses, ASN007 RD - Cancer, Malignancy | Phase 1 | Completed | Asana BioSciences | 49 | 2018-01-19 | 2020-07-09 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies palifosfamide-tris - Malignancy, Cancer | Phase 1 | Completed | Alaunos Therapeutics | 22 | 2010-12-01 | 2026-09-29 |
| Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors Olaratumab - Malignancy, Metastasis | Phase 1 | Completed | Eli Lilly and Company | 16 | 2010-09-01 | 2017-04-14 |
| Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas Debio 1143 (AT-406) - Cancer, Solid Tumors | Phase 1 | Completed | Debiopharm International SA | 51 | 2010-03-29 | 2018-12-27 |
| Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy bendamustine - Malignancy | Phase 1 | Completed | Cephalon | 6 | 2009-05-01 | 2012-04-23 |
| Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors CVX-060 - Advanced Solid Tumors, Neoplasms | Phase 1 | Completed | Pfizer | 34 | 2008-01-01 | 2015-01-26 |
| Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD) Rifaximin - Malignancy, Bone Marrow Transplantation | Phase 1 | Completed | Emory University | 20 | 2007-04-01 | 2013-11-27 |
| A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors CVX-045 - Advanced Solid Tumors, Neoplasms | Phase 1 | Completed | Pfizer | 40 | 2007-02-01 | 2010-12-13 |
Neoplasms (17) · Neoplasm Metastasis (3) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Hematologic Neoplasms (2) · Lymphoma (2) · Multiple Myeloma (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Head and Neck Neoplasms (1) · Infections (1)
Neoplasms by Histologic Type (7) · Hemic and Lymphatic Diseases (5) · Neoplasms by Site (5) · Lymphatic Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Hematologic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lung Diseases (3) · Lymphoproliferative Disorders (3)
Bendamustine Hydrochloride (2) · Capecitabine (1) · Gemcitabine (1) · Ipilimumab (1) · Lipopolysaccharides (1) · N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide (1) · Nivolumab (1) · Rifaximin (1) · Rituximab (1) · Tetanus Toxoid (1) · isophosphamide mustard (1) · olaratumab (1)
Pfizer (2) · Akeso (1) · Alaunos Therapeutics (1) · Asana BioSciences (1) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Cephalon (1) · Cyteir Therapeutics, Inc. (1) · CytoMed Therapeutics Pte Ltd (1) · Debiopharm International SA (1) · Eli Lilly and Company (1) · Emory University (1) · Hexin (Suzhou) Pharmaceutical Technology Co., Ltd (1) · Patrick Wagner, MD, FACS (1) · Shenzhen University General Hospital (1)
United States (11) · China (2) · Australia (1) · Canada (1) · Japan (1) · Netherlands (1) · Singapore (1) · Spain (1) · Switzerland (1)
Alex HL Wong, MMedSc (1) · Anand D Jeyasekharan, Dr (1) · Claudio Zanna, MD (1) · Jieming Zeng, Dr (1) · John Horan, MD (1) · Li Yu, Dr (1) · Markus Renschler, MD (1) · Natalie Grover, MD (1)
PMID 25716544, PMID 39609274, PMID 39976700
2017 (1), R01CA294033 (1)